/PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and.
Share this article
Share this article
Dr. Brownstein, an esteemed epidemiologist, researcher at Boston Children s Hospital and professor at Harvard Medical School, will assist on MINDCURE s digital technology, data optimization and patient data security within iSTRYM, its psychedelic digital therapeutics platform
VANCOUVER, BC, May 19, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( MINDCURE or the Company ) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce the addition of Dr. John Brownstein as Advisor to the Company. Dr. Brownstein, the Chief Innovation Officer at Boston Children s Hospital and a Professor of Medicine at the Harvard Medical School, is world-renowned for his pioneering approach to data management and technology within health care. The HealthMap system he founded was the first electronic disease surveillance program to issue an alert for COVID-19 in late December of 2019. Dr. Brownst
MINDCURE Announces Experienced Finance Executive Michael Wolfe as CFO and appoints Larissa Chaikowsky to its Board of Directors
News provided by
Share this article
Share this article
Mr. Wolfe has extensive capital markets and debt and equity financing experience; Ms. Chaikowsky, the COO at BMO Wealth Management, has significant expertise in corporate governance, human resources and operational risk management
VANCOUVER, BC, April 22, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( MINDCURE or the Company ) a leader in advanced proprietary technology for psychedelic therapy, is pleased today to announce the hiring of Michael Wolfe as the company s new Chief Financial Officer. Mr. Wolfe possesses over 30 years of financial leadership and private equity experience and most recently served as the CFO at Baylin Technologies, a TSX-listed company in the wireless communications industry. In an additional appointment also announced today, MINDCUR
In recent years, there has been a re-emergence in the study of psychedelic drugs as a form of therapeutic treatment. After their height in popularity during the 1950s to early 1970s, psychedelics are now re-entering the medical field. Currently, psychedelics such as LSD, psilocybin, and MDMA among others are being studied for their effectiveness in treating patients diagnosed with anxiety, depression, addiction, PTSD, and traumatic brain injuries.
While recent research on psychedelics as a form of therapeutic treatment is still under development, research centers such as the NYU Langone Center for Psychedelic Medicine and Johns Hopkins Medicine (alongside multiple others) are allocating resources towards the study of psychedelics in medicine.
LSD and the bike ride that changed the world Known as Bicycle Day, on April 19 a young Albert Hofmann took a trip that revolutionized the face of psychedelics.
Author of the article: Sam Riches
Publishing date: Apr 19, 2021 • 3 hours ago • 8 minute read On April 19, 1943, Swiss chemist Albert Hofmann intentionally dosed himself with LSD. Photo by AFP/Getty Images, Sam Riches, illustration by Sam Riches
Article content
This story first appeared in Weekend Dispensary, a weekly newsletter from The GrowthOp. Signup now to get a story delivered to your inbox every Saturday.
In the spring of 1943, Swiss chemist Albert Hofmann took a bicycle trip like no other.